Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: results of AFCAPS/TexCAPS. Air Force/Texas Coronary Atherosclerosis Prevention Study - Wikidata - thesis-toulmin - TriplyDB

Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: results of AFCAPS/TexCAPS. Air Force/Texas Coronary Atherosclerosis Prevention Study

Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: results of AFCAPS/TexCAPS. Air Force/Texas Coronary Atherosclerosis Prevention Study

http://www.wikidata.org/entity/Q29617822

about

The 3-hydroxy-3-methylglutaryl-coenzyme A reductase inhibitors, simvastatin, lovastatin and mevastatin inhibit proliferation and invasion of melanoma cells Fibrates are an essential part of modern anti-dyslipidemic arsenal: spotlight on atherogenic dyslipidemia and residual risk reduction A comprehensive review on metabolic syndrome Statins and the risk of lung cancer: a meta-analysis Statins for primary prevention of venous thromboembolism HMG CoA reductase inhibitors (statins) for people with chronic kidney disease not requiring dialysis Combined therapy with statins and fibrates for people with dyslipidaemia Statins for the primary prevention of cardiovascular disease Statins for the primary prevention of cardiovascular disease Chronotherapy versus conventional statins therapy for the treatment of hyperlipidaemia Interventions to improve adherence to lipid lowering medication Combined therapy with statins and fibrates for people with dyslipidaemia Statins and fibrates for preventing melanoma Interventions to improve adherence to lipid lowering medication The thresholds for statistical and clinical significance - a five-step procedure for evaluation of intervention effects in randomised clinical trials Risk factor thresholds: their existence under scrutiny Effect of rosuvastatin on outcomes in chronic haemodialysis patients - design and rationale of the AURORA study.Relation of different measures of low-density lipoprotein cholesterol to risk of coronary artery disease and death in a meta-regression analysis of large-scale trials of statin therapy Statin adverse effects : a review of the literature and evidence for a mitochondrial mechanism Opening a new lipid "apo-thecary": incorporating apolipoproteins as potential risk factors and treatment targets to reduce cardiovascular risk Efficacy of statins for primary prevention in people at low cardiovascular risk: a meta-analysis Jupiter to earth: a statin helps people with normal LDL-C and high hs-CRP, but what does it mean?Are statins diabetogenic?Ezetimibe therapy: mechanism of action and clinical update Pleiotropic effects of statins Regulatory challenges for new drugs to treat obesity and comorbid metabolic disorders Statin adherence and risk of acute cardiovascular events among women: a cohort study accounting for time-dependent confounding affected by previous adherence Should women be offered cholesterol lowering drugs to prevent cardiovascular disease? Yes Rising statin use and effect on ischemic stroke outcome Are statins anti-inflammatory?Treating patients with low high-density lipoprotein cholesterol: choices, issues and opportunities A review of clinical trials in dietary interventions to decrease the incidence of coronary artery disease The effects of cholesterol lowering with simvastatin on cause-specific mortality and on cancer incidence in 20,536 high-risk people: a randomised placebo-controlled trial [ISRCTN48489393]A Prospective Study of Pravastatin in the Elderly at Risk (PROSPER): Screening Experience and Baseline Characteristics Nevirapine and efavirenz elicit different changes in lipid profiles in antiretroviral-therapy-naive patients infected with HIV-1 The need for a large-scale trial of fibrate therapy in diabetes: the rationale and design of the Fenofibrate Intervention and Event Lowering in Diabetes (FIELD) study. [ISRCTN64783481]The pivotal role of cholesterol absorption inhibitors in the management of dyslipidemia Diuretics: again the first step in the treatment of most patients with hypertension Comparison of rosuvastatin and atorvastatin for lipid lowering in patients with type 2 diabetes mellitus: results from the URANUS study Evidence-based prescribing of statins: a developing world perspective.

P2860

Q21093314-F6469C4E-D71C-4E6E-8D6A-E9D33F178261 Q21246041-A6011379-F261-4229-91EF-158F71FBE678 Q21284500-17CE86DE-3C72-4B9D-B069-7A10969BC91D Q21559688-E41E5BE1-613A-4E26-9469-348F3CFDB632 Q24187238-0708D391-F5FA-4A4E-A440-7690006F3461 Q24194514-97E6BCE2-915A-4C1E-B3D8-950C8D6D7FAC Q24195172-7A697175-EB16-4D77-A8ED-7CC59A4EE4EA Q24201513-71D54ACF-01C7-4A4D-A687-B59FD1C7809E Q24234813-B52A4B16-5AE2-4C55-AB76-C413A6EC07D5 Q24235790-116DE695-1894-45B0-ADB1-65CE1DDE2BFE Q24236817-78CAA21B-336C-49CB-940D-A7C9BE19DA0A Q24243737-89756B91-9BAA-4EDB-9B6F-A746F253C165 Q24245521-08A5F570-8FE1-409B-AD9F-01FA53B6A2AE Q24245739-68E832D2-28A9-467E-9F9E-8071D979A4C0 Q24288961-F0EE9CB9-1862-488C-AF3E-0311EC2B8489 Q24527206-C334BFDC-5CFB-4AE9-B6B9-2C6271D10A28 Q24531203-2F037256-DC27-403D-9414-B6BD65CE131B Q24594496-CF279A92-6001-4278-ADD6-E2CBA43AC20E Q24603957-83C932D5-2801-4E94-9073-CFA7D4F5359A Q24626884-1C2905CC-1B17-45F4-925B-803ECA740866 Q24628361-F3116B14-5E71-4F81-9A63-881D068D1063 Q24630160-B2B9B057-F2BF-43FE-AA2C-8B40EB92E8DC Q24630205-E29EE9F0-B542-442C-8A31-9D317D05F68D Q24630302-B5ED5CED-ECC5-402A-B9D9-685AC2144A3C Q24647863-F8157C2F-1069-4616-82AC-7A789E06C2C8 Q24658031-85B62A66-B1EF-46FF-A332-6B1213E5D60B Q24658518-38C7C625-F0D2-41D6-B49E-5C6C80AEF49F Q24685830-90A5CCC3-C11B-432C-A3BE-208BA1C70FD0 Q24792305-E599815E-9165-43BE-B50B-650E1AA190A0 Q24792912-F6DDEDE7-CF07-4D55-8326-34857B3DA63D Q24793111-38A73832-93B3-4E0D-932A-00F174B44A55 Q24793178-19249688-A361-44FD-B9E3-F6FC36A651A8 Q24793837-A75907BF-769D-499E-9C35-61185D7C5278 Q24794358-A18BC133-1EFD-40CC-BB5C-613B8C67A9B6 Q24802369-45E7B9E6-DE34-40A3-A911-BC2762996C55 Q24804541-C09E5967-230D-48B0-9553-21635BA371EB Q24805607-9D852100-EE52-403E-9393-A753A481BFEF Q24806951-D9F1301C-6A09-4C7E-82C0-267917BC3482 Q24814804-FCEED919-B8C0-4F49-82F6-B6C5DE15AADE Q25255887-577065F9-E08E-4406-A1B1-D63B7AEFDA15

P2860

Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: results of AFCAPS/TexCAPS. Air Force/Texas Coronary Atherosclerosis Prevention Study

http://www.wikidata.org/entity/Q29617822

description

1998 nî lūn-bûn

@nan

1998 թուականի Մայիսին հրատարակուած գիտական յօդուած

@hyw

1998 թվականի մայիսին հրատարակված գիտական հոդված

@hy

1998年の論文

@ja

1998年論文

@yue

1998年論文

@zh-hant

1998年論文

@zh-hk

1998年論文

@zh-mo

1998年論文

@zh-tw

1998年论文

@wuu

name

Primary prevention of acute co ...... herosclerosis Prevention Study

@ast

Primary prevention of acute co ...... herosclerosis Prevention Study

@en

type

label

Primary prevention of acute co ...... herosclerosis Prevention Study

@ast

Primary prevention of acute co ...... herosclerosis Prevention Study

@en

prefLabel

Primary prevention of acute co ...... herosclerosis Prevention Study

@ast

Primary prevention of acute co ...... herosclerosis Prevention Study

@en

P1433

Q29617822-D6F4D933-4216-46AD-B4D7-F56E405AB34D

P1476

Q29617822-119A462C-9448-48D2-A453-96D1885021AE

P2093

Q29617822-1FBCC6AD-4DF3-48A0-B018-C882D8F5E62A

Q29617822-518F5B6D-2BD8-45DB-864A-D833C49C2757

Q29617822-739A7A26-88A2-4B99-907A-89C7B9DD3D0E

Q29617822-8B0D9351-50AB-45C7-9AE6-AF0EAF45C167

Q29617822-968AB165-19D6-458B-9837-B214A1B601AB

Q29617822-A0AAD30A-AE67-4E30-990F-42D3A8BB0709

Q29617822-B0D76B09-6587-4725-94DF-7ED91595FF1B

Q29617822-C740F37E-2ACD-4DD7-8BC0-0D664C895C9E

Q29617822-D5CDA28F-0A39-48D7-B217-7A3B4A08D8CB

Q29617822-E121B393-1B57-4E9A-B601-1FDF3C616A87

P304

Q29617822-FA76BC25-311F-4A62-B31E-EB9ECBF0545D

P31

Q29617822-1E7C8B86-BFF0-41D3-9C17-C97468418227

P3181

Q29617822-8805671B-83F0-4D0B-89E2-63D369D64D0F

P356

Q29617822-4CB9A7BB-9448-4278-BE8E-BF723FF62935

P407

Q29617822-4BC4C999-8E61-4B27-BFF2-DA49B80BC16B

P433

Q29617822-6A204E8E-651A-4B84-8B62-632E3155D7D7

P478

Q29617822-C51F437B-6ECA-4441-BCBD-C6F7E09AAA04

P577

Q29617822-CDD0BE75-281A-417A-8556-F49F5B1235AF

P5875

Q29617822-F291D180-E1C4-41F6-B92A-DFDBB9B12BF6

P698

Q29617822-35946C47-940C-485D-A4CC-4D44339E807B

P921

Q29617822-EDF17463-7F23-4426-8107-D2C4E25C4E9F

P3181

P356

JAMA.279.20.1615

P1433

Journal of the American Medical Association

P1476

Primary prevention of acute co ...... herosclerosis Prevention Study

@en

P2093

Beere PA

http://www.w3.org/2001/XMLSchema#string

Clearfield M

http://www.w3.org/2001/XMLSchema#string

Downs JR

http://www.w3.org/2001/XMLSchema#string

Gotto AM Jr

http://www.w3.org/2001/XMLSchema#string

Kruyer W

http://www.w3.org/2001/XMLSchema#string

Langendorfer A

http://www.w3.org/2001/XMLSchema#string

Shapiro DR

http://www.w3.org/2001/XMLSchema#string

Stein EA

http://www.w3.org/2001/XMLSchema#string

Weis S

http://www.w3.org/2001/XMLSchema#string

Whitney E

http://www.w3.org/2001/XMLSchema#string

P304

1615-22

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P3181

716472

http://www.w3.org/2001/XMLSchema#string

P356

10.1001/JAMA.279.20.1615

http://www.w3.org/2001/XMLSchema#string

P407

P433

20

http://www.w3.org/2001/XMLSchema#string

P478

279

http://www.w3.org/2001/XMLSchema#string

P577

1998-05-27T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

236299244

http://www.w3.org/2001/XMLSchema#string

P698

9613910

http://www.w3.org/2001/XMLSchema#string

P921

atherosclerosis